18F-FDG PET/CT Metabolic Response With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent 4/6 Kinase Inhibitors.

Abstract

ABSTRACT:

Dysregulation of the cyclin D-CDK4/6-INK4-RB pathway, which leads to uncontrolled cell proliferation, is frequently observed in breast cancer. Recently, 3 CDK4/6 inhibitors have been FDA approved as first-line treatment for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Despite promising clinical results, the metabolic response to treatment with these new drugs has not been elaborately demonstrated yet. Herein, we presented a patient with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer who demonstrated a complete metabolic response on 18F-FDG PET/CT to treatment with a CDK4/6 inhibitor (ribociclib).

• Authors: Nuh Filizoglu, Salih Ozguven, Tanju Yusuf Erdil
• Journal: Clinical nuclear medicine (Clin Nucl Med) Vol. 47 Issue 9 Pg. e605-e606 (Sep 01 2022) ISSN: 1536-0229 [Electronic] United States
• PMID: 35930715 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Chemical References

• Cyclins
• Protein Kinase Inhibitors
• Fluorodeoxyglucose F18
• ERBB2 protein, human
• Receptor, ErbB-2
• Cyclin-Dependent Kinase 4
• Cyclin-Dependent Kinase 6

Topics

• Antineoplastic Combined Chemotherapy Protocols
• Breast Neoplasms (diagnostic imaging, drug therapy, metabolism)
• Cyclin-Dependent Kinase 4 (therapeutic use)
• Cyclin-Dependent Kinase 6 (therapeutic use)
• Cyclins (therapeutic use)
• Female
• Fluorodeoxyglucose F18
• Humans
• Positron Emission Tomography Computed Tomography
• Protein Kinase Inhibitors (pharmacology, therapeutic use)
• Receptor, ErbB-2
• Triple Negative Breast Neoplasms